Phase 3 trials of pembrolizumab in prostate, lung cancer miss primary endpoints

Two phase 3 trials evaluating pembrolizumab in combination with additional agents failed to meet their primary endpoints, according to the agent’s manufacturer.
One of the trials, KEYNOTE-641, will be discontinued at the recommendation of an independent data safety monitoring committee, a Merck press release stated.
The randomized, double-blind KEYNOTE-641 trial assessed pembrolizumab (Keytruda, Merck), an anti-PD-1 therapy, vs. placebo among 1,240 men with metastatic castration-resistant prostate cancer who also received enzalutamide (Xtandi; Astellas, Pfizer) and androgen deprivation

Two phase 3 trials evaluating pembrolizumab in combination with additional agents failed to meet their primary endpoints, according to the agent’s manufacturer.
One of the trials, KEYNOTE-641, will be discontinued at the recommendation of an independent data safety monitoring committee, a Merck press release stated.
The randomized, double-blind KEYNOTE-641 trial assessed pembrolizumab (Keytruda, Merck), an anti-PD-1 therapy, vs. placebo among 1,240 men with metastatic castration-resistant prostate cancer who also received enzalutamide (Xtandi; Astellas, Pfizer) and androgen deprivation